Literature DB >> 20209345

Ocular lesions in HTLV-1 infected patients from Salvador, State of Bahia: the city with the highest prevalence of this infection in Brazil.

Regina Helena Rathsam-Pinheiro1, Ney Boa-Sorte, Cristina Castro-Lima-Vargens, Carlos Aldir Pinheiro, Humberto Castro-Lima, Bernardo Galvão-Castro.   

Abstract

In order to determine the prevalence of ocular lesions in HTLV-1 infected patients in Salvador Bahia, a transversal study was conducted on 140 HTLV-1 infected patients (90 asymptomatic and 50 tropical spastic paraparesis/HTLV-1-associated myelopathy) between June 2004 and November 2005. The ophthalmological examination included visual acuity measurement, ocular motility, biomicroscopy of the anterior and posterior chambers, intraocular pressure and evaluation of lachrymal secretion. Observation verified 4 (2.8%) out of 140 patients with uveitis (two patients had intermediate uveitis and two had pan-uveitis) and 39 (36.4%) out of 107 patients with keratoconjunctivitis sicca. The prevalence of Keratoconjunctivitis sicca was significantly higher among the TSP/HAM patients (OR age adjusted=3.64; 95%CI 1.59-8.32). Uveitis and corneal opacities were also important findings, indicating the strong need for periodic ophthalmological follow-up in all HTLV-1 subjects.

Entities:  

Mesh:

Year:  2009        PMID: 20209345     DOI: 10.1590/s0037-86822009000600004

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  7 in total

1.  Integrative and Multidisciplinary Care for People Living With Human T-Cell Lymphotropic Virus in Bahia, Brazil: 20 Years of Experience.

Authors:  Bernardo Galvão-Castro; Maria Fernanda Rios Grassi; Ana Verena Galvão-Castro; Aidê Nunes; Ana Karina Galvão-Barroso; Thessika Hialla Almeida Araújo; Regina Helena Rathsam-Pinheiro; Ceuci Lima Xavier Nunes; Adriele Ribeiro; Monique Lírio; Noilson Lázaro Gonçalves; Sônia Lúcia Rangel; Cristiane Maria Carvalho Costa Dias; Daniele Piai Ozores; Selena Márcia Dubois-Mendes; Isabela Lima; André Luís Pereira Silva; Washington Luiz Abreu de Jesus; Fred Luciano Neves Santos; José Guilherme Reis de Oliveira; Yscela Vanessa Pimentel de Moraes; Adijeane Oliveira de Jesus; Francisco Daltro; Ney Boa-Sorte; Humberto Castro-Lima; Maria Luísa Carvalho Soliani
Journal:  Front Med (Lausanne)       Date:  2022-06-07

2.  CNS diseases and uveitis.

Authors:  Pia Allegri; Roberto Rissotto; Carl P Herbort; Ugo Murialdo
Journal:  J Ophthalmic Vis Res       Date:  2011-10

3.  Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan.

Authors:  Shuntaro Tsutsumi; Tomoo Sato; Naoko Yagishita; Junji Yamauchi; Natsumi Araya; Daisuke Hasegawa; Misako Nagasaka; Ariella L G Coler-Reilly; Eisuke Inoue; Ayako Takata; Yoshihisa Yamano
Journal:  Orphanet J Rare Dis       Date:  2019-10-21       Impact factor: 4.123

4.  Mechanism of Secondary Glaucoma Development in HTLV-1 Uveitis.

Authors:  Yuan Zong; Koju Kamoi; Naoko Ando; Hisako Kurozumi-Karube; Kyoko Ohno-Matsui
Journal:  Front Microbiol       Date:  2022-06-02       Impact factor: 6.064

5.  HTLV-1 uveitis.

Authors:  Koju Kamoi; Manabu Mochizuki
Journal:  Front Microbiol       Date:  2012-07-24       Impact factor: 5.640

6.  IFNG +874A/T Polymorphism Among Asymptomatic HTLV-1-Infected Individuals Is Potentially Related to a Worse Prognosis.

Authors:  Maria A F Queiroz; Vânia N Azevedo; Ednelza da S G Amoras; Tuane C F Moura; Marluísa de O Guimarães Ishak; Ricardo Ishak; Antonio C R Vallinoto; Rosimar N Martins Feitosa
Journal:  Front Microbiol       Date:  2018-05-18       Impact factor: 5.640

7.  Revisiting Keratoconjunctivitis sicca associated with Human T-Cell Lymphotropic Virus Type 1: prevalence, clinical aspects and proviral load.

Authors:  Regina Helena Rathsam-Pinheiro; Ney Boa-Sorte; Maria Fernanda Rios Grassi; Úrsula Cury Copello; Karla Tayrine Silva Guimarães Rios; Thessika Araújo; Bernardo Galvão-Castro
Journal:  Braz J Infect Dis       Date:  2019-05-03       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.